Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 89, Issue 3, 2014, Pages 539-546

  Dholakia, Avani S ^a   Chaudhry, Muhammad ^b   Leal, Jeffrey P ^b   Chang, Daniel T ^c   Raman, Siva P ^b   Hacker Prietz, Amy ^a   Su, Zheng ^c   Pai, Jonathan ^c   Oteiza, Katharine E ^a   Griffith, Mary E ^a   Wahl, Richard L ^b   Tryggestad, Erik ^a   Pawlik, Timothy ^b   Laheru, Daniel A ^b   Wolfgang, Christopher L ^b   Koong, Albert C ^c   Herman, Joseph M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; METABOLISM; PATHOLOGY; RADIOTHERAPY; REGRESSION ANALYSIS; TUMORS;

CONFIDENCE INTERVAL; COX REGRESSION ANALYSIS; LOCALLY ADVANCED PANCREATIC CANCERS; METABOLIC TUMOR VOLUMES; MULTI VARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY (PET); STANDARDIZED UPTAKE VALUES; STEREOTACTIC BODY RADIATION THERAPY;

POSITRON EMISSION TOMOGRAPHY;

GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; GLYCOLYSIS; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STEREOTACTIC BODY RADIATION THERAPY; TOTAL LESION GLYCOLYSIS; TUMOR LOCALIZATION; TUMOR VOLUME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BLOOD GLUCOSE; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; HUMANS; INDUCTION CHEMOTHERAPY; LIVER; MALE; MIDDLE AGED; MULTIMODAL IMAGING; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RADIOSURGERY; REGRESSION ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84902213600     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.02.031     Document Type: Article

References (31)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. T.A. Sohn, C.J. Yeo, and J.L. Cameron et al. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators J Gastrointest Surg 4 2000 567 579
3. Cancer Facts and Figures. March 13 2013. Available at: www.cancer.org/research/cancerfactsfigures/acspc-031941. Accessed July 26, 2013.
4. J.M. Herman, M.J. Swartz, and C.C. Hsu et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital J Clin Oncol 26 2008 3503 3510
5. K.J. Redmond, C.L. Wolfgang, and E.A. Sugar et al. Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas Ann Surg Oncol 17 2010 3112 3119
6. M.A. Tempero, J.P. Arnoletti, and S.W. Behrman et al. Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN Guidelines J Natl Compr Canc Netw 10 2012 703 713
7. C.L. Wolfgang, J.M. Herman, and D.A. Laheru et al. Recent progress in pancreatic cancer CA Cancer J Clin 63 2013 318 348
8. S. Bang, H.W. Chung, and S.W. Park et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer J Clin Gastroenterol 40 2006 923 929
9. E.C. Ford, J. Herman, and E. Yorke et al. 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy J Nucl Med 50 2009 1655 1665
10. D. Schellenberg, A. Quon, and A.Y. Minn et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy Int J Radiat Oncol Biol Phys 77 2010 1420 1425
11. M. Kuwatani, H. Kawakami, and K. Eto et al. Modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: Comparison between FDG-PET, CT, and serum tumor markers Intern Med 48 2009 867 875
12. M. Choi, L.K. Heilbrun, and R. Venkatramanamoorthy et al. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer Am J Clin Oncol 33 2010 257 261
13. A. Asagi, K. Ohta, and J. Nasu et al. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: Impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence Pancreas 42 2013 11 19
14. H. Kittaka, H. Takahashi, and H. Ohigashi et al. Role of (1)(8)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer World J Surg 37 2013 169 178
15. S.C. Chan, W.H. Kuo, and H.M. Wang et al. Prognostic implications of post-therapy F-FDG PET in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy Ann Nucl Med 27 2013 710 719
16. R. Lim, A. Eaton, and N.Y. Lee et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma J Nucl Med 53 2012 1506 1513
17. P. Lee, J.G. Bazan, and P.W. Lavori et al. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer Clin Lung Cancer 13 2012 52 58
18. P. Lee, D.K. Weerasuriya, and P.W. Lavori et al. Metabolic tumor burden predicts for disease progression and death in lung cancer Int J Radiat Oncol Biol Phys 69 2007 328 333
19. P. Jayachandran, R.K. Pai, and A. Quon et al. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer Int J Radiat Oncol Biol Phys 84 2012 471 477
20. J.G. Bazan, A.C. Koong, and D.S. Kapp et al. Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal J Nucl Med 54 2013 27 32
21. M.K. Song, J.S. Chung, and H.J. Shin et al. Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma Leuk Res 37 2013 58 63
22. W. Huang, T. Zhou, and L. Ma et al. Standard uptake value and metabolic tumor volume of (1)(8)F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer Eur J Nucl Med Mol Imaging 38 2011 1628 1635
23. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
24. M.M. Oken, R.H. Creech, and D.C. Tormey et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
25. M.A. Lodge, M.A. Chaudhry, and R.L. Wahl Noise considerations for PET quantification using maximum and peak standardized uptake value J Nucl Med 53 2012 1041 1047
26. A.C. Koong, V.K. Mehta, and Q.T. Le et al. Pancreatic tumors show high levels of hypoxia Int J Radiat Oncol Biol Phys 48 2000 919 922
27. O. Warburg On respiratory impairment in cancer cells Science 124 1956 269 270
28. R.J. DeBerardinis, J.J. Lum, and G. Hatzivassiliou et al. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation Cell Metab 7 2008 11 20
29. N.C. Denko Hypoxia, HIF1 and glucose metabolism in the solid tumour Nat Rev Cancer 8 2008 705 713
30. R.L. Wahl, H. Jacene, and Y. Kasamon et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 suppl 1 2009 122S 150S
31. C.A. Iacobuzio-Donahue, B. Fu, and S. Yachida et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer J Clin Oncol 27 2009 1806 1813